This content is machine translated Psoriasis in locations that are difficult to treat New study data on IL-23 inhibition When psoriasis manifests in palmoplantar and intertriginous regions or on the nails, this often poses a therapeutic challenge. Several recently presented analyses on the effects of anti-IL-23p19 antibodies currently approved...…
View Post 4 min This content is machine translated Inflammatory memory in psoriasis Timing of biologics therapy is crucial The pathogenesis of psoriasis is complex, but is becoming increasingly better understood. With the modern substance classes of interleukin (IL)-17 and IL-23 inhibitors, highly effective biologics are now available for…
View Post 9 min This content is machine translated System therapy for psoriasis Expanded possibilities thanks to practical innovations Compared to the past, there are now more and more effective systemic therapies available. This has been helped by a surge in innovation that has produced a wide range of…
View Post 5 min This content is machine translated Biologics therapy for psoriasis Better outcomes through innovative methods of therapy management Personalized medicine is also becoming increasingly important in the field of inflammatory skin diseases. Currently, IL-17 and IL-23 inhibitors are most effective in moderate to severe psoriasis, but the response…
View Post 8 min This content is machine translated Psoriasis vulgaris Practice-oriented recommendations for system therapy Fortunately, developments in recent years have led to the effective treatment of many patients with moderate to severe psoriasis. In addition to classical immunosuppressants, several biologics and a small molecule…
View Post 4 min This content is machine translated Biologics for psoriasis “Drug Survival” under the microscope The era of biologics has revolutionized the treatment options for patients with moderate to severe psoriasis in recent decades. Drug survival is an indicator of the longer-term efficacy and safety…
View Post 3 min This content is machine translated Guselkumab in psoriatic arthritis Early response predicted Recent analyses of a heterogeneous group of patients with active psoriatic arthritis (PsA) show that early treatment response with respect to skin psoriasis and enthesitis is a predictor of sustained…
View Post 4 min This content is machine translated Psoriatic arthritis (PsA) Guselkumab in joint involvement – successful interim results Long-term data from the pivotal DISCOVER-2 study show that treatment with guselkumab resulted in sustained improvements in joint and skin symptoms and functional capacity over a two-year period in biologic-naïve…
View Post 3 min This content is machine translated Guselkumab Now also available as a patient-friendly ready-to-use pen The device, which was recently approved by Swissmedic, enables psoriasis sufferers to self-administer the biologic in single doses. It is currently the only IL23 inhibitor available in Switzerland in the…
